Vitreous Levels of Cysteine-rich 61 in Patients With Proliferative Diabetic Retinopathy
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
To determine the vitreous levels of fractalkine, cysteine-rich 61 (Cyr61), and VEGF in
patients with PDR. Verifying that it is greater to that found in non-diabetic patients with
different non-angiogenetic diseases.